Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
Neuronetics, a leader in transcranial magnetic stimulation, will showcase real-world clinical data on NeuroStar Advanced Therapy for Mental Health at the Clinical TMS Society Annual Meeting in West Palm Beach, Florida, from June 10-12, 2021. Highlights include presentations on clinical outcomes from the NeuroStar Outcomes Registry, covering efficacy comparisons and treatment protocols. Neuronetics, as a Platinum Sponsor, aims to enhance awareness of TMS's benefits for major depressive disorder. With over 4 million treatment sessions delivered, the company continues to influence mental health treatment.
Neuronetics, a medical technology company listed on NASDAQ under the symbol STIM, will present at The JMP Securities Life Sciences Conference on June 17, 2021, at 10:00 AM ET. CEO Keith Sullivan and CFO Steve Furlong will lead the discussion. A live audio webcast will be available on the company's investor relations page, with an archive accessible for 90 days post-event. Neuronetics focuses on developing products like the NeuroStar® Advanced Therapy System, a TMS treatment approved by the FDA for major depressive disorder.
Neuronetics has appointed Todd Cushman as Vice President of Business Development, effective immediately. This strategic move aims to enhance the company's international strategy and commercial operations, particularly for its NeuroStar Advanced Therapy for treating Major Depressive Disorder. Cushman brings over 35 years of experience, having previously held leadership roles at Bioness, Medtronic, and Acumed. His expertise is expected to drive market innovation in mental health treatment.
Neuronetics, a medical technology company, announced participation at the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 9:40 AM ET. CEO Keith Sullivan and CFO Steve Furlong will present details about the company’s innovative products designed to enhance the lives of patients with psychiatric disorders. A live audio webcast will be available on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics is known for its NeuroStar® Advanced Therapy System, FDA-cleared for treating major depressive disorder.
Summary not available.
Neuronetics (NASDAQ: STIM) reported its Q1 2021 results with revenues of $12.3 million, up 7% from Q1 2020. U.S. treatment session revenue rose 18% to $9.6 million, while international revenue skyrocketed 63%. However, the sales of the NeuroStar system decreased by 32% year-over-year. The gross margin improved to 81.9%, and operating expenses decreased to $17 million. The company ended Q1 with $121.3 million in cash, up significantly from last year. The full-year guidance has been adjusted, expecting worldwide revenue between $59 million and $63 million.
Neuronetics, a medical technology company, announced its participation in the American Psychiatric Association’s Annual Meeting, held virtually from May 1-3, 2021. The company will present real-world clinical data on its NeuroStar Advanced Therapy for treating Major Depressive Disorder (MDD). Key presentations will cover outcomes from over 5,000 patients and the effectiveness of transcranial magnetic stimulation (TMS) in patients with MDD and comorbidities. Neuronetics continues to lead in depression treatment, having delivered 3.5 million treatments across more than 900 locations in the U.S.
MALVERN, Pa., April 20, 2021 – Neuronetics, a commercial-stage medical technology company, announced plans to release its first quarter financial results before market open on May 4, 2021. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time the same day. The call will be available via webcast on the company's investor relations website. Neuronetics specializes in products for psychiatric disorders, notably the NeuroStar® Advanced Therapy System, cleared by the FDA for treating major depressive disorder.
Neuronetics, Inc. (NASDAQ: STIM) announced the retirement of Brian Farley as Chairman of the Board after 11 years, effective May 27, 2021. Robert Cascella, appointed to the Board on April 1, 2021, will succeed him. Farley has been instrumental in commercializing the NeuroStar Advanced Therapy for mental health. CEO Keith Sullivan expressed gratitude for Farley’s contributions and optimism for Cascella’s leadership. The Board will comprise seven members post-transition.
Neuronetics, Inc. (NASDAQ: STIM) announced the appointment of Robert A. Cascella to its Board of Directors, expanding the board to eight members. Cascella brings over 30 years of healthcare leadership experience, including roles at Royal Philips and Hologic. His expertise is expected to guide Neuronetics in enhancing its market position, particularly with the NeuroStar Advanced Therapy for Mental Health. This therapy offers a non-invasive treatment for major depressive disorder, approved by the FDA for patients who haven't responded to other medications.